Business
Biomira President & CEO to Participate in Cancer Immunotherapy Focus Session at BIO CEO & Investor Conference
Biomira President & CEO to Participate in Cancer Immunotherapy Focus Session at BIO CEO & Investor Conference.
About this update from Skrr Exploration, Inc.
[{"type":"text","content":"\n\n\n\n\nEDMONTON, Feb. 8 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today\nannounced that Alex McPherson, MD, Ph.D., President and Chief Executive\nOfficer, is scheduled to participate in a focus session entitled \"Cancer\nImmunotherapies Coming of Age\" at the Biotechnology Industry Organization's\n8th Annual BIO CEO & Investor Conference at 9:00 a.m. EST on Tuesday, \nFebruary 14, 2006. The conference is to be held at The Waldorf-Astoria in \nNew York City.\nDr. McPherson will be joined on the panel by John P. Longenecker, PhD,\nPresident & CEO, Favrille Inc., Peter Working, PhD, Senior Vice President,\nResearch and Development, Cell Genesys, Inc., Mitchell Gold, MD, President and\nCEO, Dendreon Corporation, and Hyam Levitsky, MD, Professor of Oncology, Johns\nHopkins University School of Medicine. Mark Monane, MD, Managing Director of\nEquity Research, Biotechnology and Life Sciences, Needham and Company, LLC,\nwill serve as the panel's moderator.\nA webcast recording of the focus session can be accessed at\nhttp://ceo.bio.org/opencms/ceo/2006/index.jsp. The Web cast recording will be\navailable approximately 12 hours after the presentation and will be archived\nuntil March 14, 2006.\n\nAbout Biomira\nBiomira is a biotechnology company specializing in the development of\ninnovative therapeutic approaches to cancer management. Biomira's commitment\nto the treatment of cancer currently focuses on the development of synthetic\nvaccines and novel strategies for cancer immunotherapy.\n\n\n\n","length":1574,"tagName":"div"}]